TICKERNOMICS Sign up
Last Update: 2023-12-23 06:03:45
CASI Pharmaceuticals Inc. ( CASI ) https://www.casipharmaceuticals.com
6.70USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
CASI
340.79%
SPY
30.72%
-77.89%
CASI
SPY
112.82%
-83.86%
CASI
SPY
201.04%
-57.05%
CASI
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
91.44
87.21
0.02
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-1.88
1.85
1.37
-30.44
0.00
1.74
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
76.34
72.00
82.17
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.6052
18.38
45.60
0.18
Other Earnings and Cash Flow Stats:
CASI Pharmaceuticals Inc. ( CASI ) Net Income TTM ($MM) is -39.75
CASI Pharmaceuticals Inc. ( CASI ) Operating Income TTM ($MM) is -9.74
CASI Pharmaceuticals Inc. ( CASI ) Owners' Earnings Annual ($MM) is -31.40
CASI Pharmaceuticals Inc. ( CASI ) Current Price to Owners' Earnings ratio is -0.78
CASI Pharmaceuticals Inc. ( CASI ) EBITDA TTM ($MM) is -8.86
CASI Pharmaceuticals Inc. ( CASI ) EBITDA Margin is 82.17%
Capital Allocation:
CASI Pharmaceuticals Inc. ( CASI ) has paid 0.00 dividends per share and bought back -0.041325000000001 million shares in the past 12 months
CASI Pharmaceuticals Inc. ( CASI ) has reduced its debt by 1.556 million USD in the last 12 months
Capital Structure:
CASI Pharmaceuticals Inc. ( CASI ) Interest-bearing Debt ($MM) as of last quarter is 0
CASI Pharmaceuticals Inc. ( CASI ) Annual Working Capital Investments ($MM) are -12
CASI Pharmaceuticals Inc. ( CASI ) Book Value ($MM) as of last quarter is 66
CASI Pharmaceuticals Inc. ( CASI ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
CASI Pharmaceuticals Inc. ( CASI ) has 47 million in cash on hand as of last quarter
CASI Pharmaceuticals Inc. ( CASI ) has 11 million of liabilities due within 12 months, and long term debt 0 as of last quarter
CASI Pharmaceuticals Inc. ( CASI ) has 13 common shares outstanding as of last quarter
CASI Pharmaceuticals Inc. ( CASI ) has 0 million USD of preferred stock value
Academic Scores:
CASI Pharmaceuticals Inc. ( CASI ) Altman Z-Score is -4.77 as of last quarter
CASI Pharmaceuticals Inc. ( CASI ) Piotroski Score is 5.00 as of last quarter
Corporate Governance:
CASI Pharmaceuticals Inc. ( CASI ) largest shareholder is Royal Bank of Canada owning 18 shares at 0.00 ($MM) value
James Huang(an insider) Bought 33300 shares of CASI Pharmaceuticals Inc. ( CASI ) for the amount of $142524.00 on 2022-09-08
45.40% of CASI Pharmaceuticals Inc. ( CASI ) is held by insiders, and 3.23% is held by institutions
CASI Pharmaceuticals Inc. ( CASI ) went public on 1996-06-11
Other CASI Pharmaceuticals Inc. ( CASI ) financial metrics:
FCF:-27.84
Unlevered Free Cash Flow:-16.62
EPS:-5.42
Operating Margin:76.34
Gross Profit Margin:72.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-165.97
Beta:0.18
Buffet's Owners Earnings:-31.40
Price to Owner's Earnings:-0.78
About CASI Pharmaceuticals Inc. ( CASI ) :
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, an antibody, which has a novel mode-of-action, blocking the inhibitory antibody checkpoint receptor FcRIIB to unlock anti-cancer immunity and enhance the efficacy of antibody-based immunotherapy in hematological malignancies and solid tumors; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; and CID-103, a human IgG1 anti-CD38 monoclonal antibody. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was founded in 1991 and is based in Beijing, the People's Republic of China.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.